1298 Miscellaneous drug categories
Reactions may be
common
, uncommon,
life-threatening
, or
commonandlife-threatening.
24 hours and substitute with formula or
expressedbreastmilk prior to the procedure.
Patient teaching
• Advise person to report any adverse
effects.
• Encourage person to void after the
procedure and regularly thereafter.
• Advise person to drink fluids regularly.
• Women who are breastfeeding should
be instructed to discontinue breastfeeding
for at least 24 hours and substitute with
formula or expressed breast milk prior to
the procedure.
gadobenate dimeglumine
MultiHance
Pregnancy risk category B3
Use in sport: Permitted
Available forms
Solutionfor injection:
334mg/mL (0.5mmol/
mL) in 5 mL, 10 mL, 15 mL, 20 mL
Indications & dosages
➤
Enhancement of magnetic resonance
imaging(MRI)ofthe liver—
Adults:
0.05mmol/kg bodyweight (0.1mL/
kg bodyweight) by IV bolus or infusion.
➤
EnhancementofMRIofthebrainandspine—
Adults:
0.1 mmol/kg bodyweight (0.2 mL/
kg bodyweight) by IV bolus or infusion.
Action
Paramagnetic contrast agent.
Route Onset
Peak
Duration
IV
Immediate Unknown 24 hrs
Adverse reactions
CNS:
convulsions, dizziness, headache,
tremor.
CV:
angina pectoris, arrhythmias,
cardiac
arrest
,
circulatory failure
, hypertension,
hypotension, tachycardia, vasodilation.
ENT:
vertigo.
GI:
abdominal pain, diarrhoea, dry mouth,
faecal incontinence, nausea, taste alteration.
GU:
acutekidneyinjury
,urinaryincontinence.
Musculoskeletal:
myalgia,
nephrogenic
systemic fibrosis
.
Respiratory:
bronchospasm
, cough, dys
pnoea, hypoxia, laryngospasm.
Skin:
erythema, rash, localised oedema,
pruritus.
Other:
anaphylactic reaction
,
angio-
oedema
, hypersensitivity, injection site pain.
Interactions
None reported.
Contraindications
Contraindicated in individuals with known
hypersensitivity to the preparation.
care considerations
• Increased risk of nephrogenic systemic
fibrosis in individuals with acute or chronic
renal failure or acute renal insufficiency,
or during the perioperative period in liver
transplantation. Renal function should
be assessed in all individuals prior to the
procedure.
• For individuals on chronic haemodialysis,
initiate haemodialysis promptly following
administrationof gadobenate dimeglumine
to increase elimination.
• Closelymonitor individualfordevelopment
of anaphylactic reaction for up to 2 hours
after administration. Ensure emergency
management equipment is available and in
correct working order.
• Monitor vital signs closely following
procedure.
• If there is a need to repeat administration,
there should be at least 7 hours between
doses.
• Due to potential for bladder radiation,
encourage person to follow adequate
hydration and to void straight after the
procedure, then regularly thereafter.
Patient teaching
• Advisepersontoreportanyadverseeffects.
